Spectral AI, Inc. (NASDAQ: MDAI)

Spectral AI, Inc., also known as MDAI, operates in the predictive medical diagnostics industry, specifically focusing on wound care. The company's primary product, the DeepView System, leverages proprietary AI algorithms and multispectral imaging (MSI) technology to distinguish between fully damaged, partially damaged, and healthy human tissue, providing a binary prediction on the wound's capacity to heal or not-heal by a specified time point in the future.

Spectral AI's main business activities revolve around the development and commercialization of its DeepView System. This system is designed to assist clinicians in making accurate, timely, and informed decisions regarding the treatment of patient wounds. The company's operations span across the United States and the United Kingdom, with plans to expand further.

The company generates revenue through the sale of its DeepView System. This predictive analytics platform combines AI algorithms and MSI imaging for an assessment of wound healing potential. The system includes two primary products: the DeepView System, a cart-based system that uses MSI technology to capture images of wounds, and the DeepView AI-Burn software, which is used to analyze the images and provide a prediction on the wound's healing potential.

Within the industry, Spectral AI holds a strong position due to its proprietary AI algorithms and MSI technology, which provide a unique and accurate assessment of wound healing potential. The system is non-invasive, non-radiation, and non-laser, making it a safer and more comfortable option for patients. Additionally, the system is designed to provide a rapid and objective assessment of wound healing potential, which can help clinicians make more informed treatment decisions.

The company's primary customers are healthcare providers, including burn centers, trauma centers, and emergency rooms, as well as wound care clinics and hospitals. The sales channel for its burn indication is supported by existing and future governmental contracts, primarily from agencies such as BARDA and the DHA, while the DFU indication will have its own separate sales channel to penetrate the podiatric and wound care clinics.

The DeepView System has received UKCA marking for use in the United Kingdom for burn indications, and the company anticipates initial sales in the UK in the second half of 2024. For the DFU indication, the company has completed its first clinical validation study in the United States and has enrolled subjects in a larger study in the UK. The company plans to submit for UKCA regulatory evaluations in mid-2024 and for FDA marketing authorization in 2025.

The DeepView System's brand names include the DeepView System and the DeepView AI-Burn software. These products represent the company's commitment to improving wound care through innovative technology.